Genetic studies in the evaluation of myeloproliferative neoplasms

被引：3

作者：

Caponetti, Gabriel C. ^{[1
]}

Bagg, Adam ^{[1
]}

机构：

[1] Univ Penn, Dept Pathol & Lab Med, Div Hematopathol, Philadelphia, PA USA

来源：

SEMINARS IN HEMATOLOGY | 2019年 / 56卷 / 01期

关键词：

mutations; genetic; myeloproliferative; myeloid; leukemia; myelofibrosis; CHRONIC NEUTROPHILIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL TRANSCRIPTS; CYTOGENETIC ABNORMALITIES; POLYCYTHEMIA-VERA; CHROMOSOMAL-ABNORMALITIES; ESSENTIAL THROMBOCYTHEMIA; FOLLOW-UP; MUTATIONS; JAK2;

D O I：

10.1053/j.seminhematol.2018.05.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myeloproliferative neoplasms that include the specific entities of chronic myeloid leukemia, chronic neutrophilic leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis are characterized by the clonal expansion of hematopoietic precursor cells and consequent neoplastic production of mature cells of myeloid, erythroid, and/or megakaryocytic lineage. Genetic studies, encompassing both cytogenetic and molecular testing, play a central and ever increasing role in the assessment of these neoplasms and are the focus of this review. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：7 / 14

页数：8

共 31 条

[1]

[Anonymous], 2017, WHO CLASSIFICATION T

[2] Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia [J].

Arpinati, Mario ;

Tolomelli, Giulia ;

Bochicchio, Maria Teresa ;

Castagnetti, Fausto ;

Amabile, Marilina ;

Bandini, Giuseppe ;

Bonifazi, Francesca ;

Stanzani, Marta ;

Rosti, Gianantonio ;

Martinelli, Giovanni ;

Baccarani, Michele .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (05) :735-740

[3] Can pegylated interferon improve the outcome of polycythemia vera patients? [J].

Crisa, Elena ;

Cerrano, Marco ;

Beggiato, Eloise ;

Benevolo, Giulia ;

Lanzarone, Giuseppe ;

Manzini, Paola Maria ;

Borchiellini, Alessandra ;

Riera, Ludovica ;

Boccadoro, Mario ;

Ferrero, Dario .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10

[4] Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms [J].

Defour, J-P ;

Chachoua, I. ;

Pecquet, C. ;

Constantinescu, S. N. .

LEUKEMIA, 2016, 30 (05) :1214-1216

[5] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Gathmann, Insa ;

Kantarjian, Hagop ;

Gattermann, Norbert ;

Deininger, Michael W. N. ;

Silver, Richard T. ;

Goldman, John M. ;

Stone, Richard M. ;

Cervantes, Francisco ;

Hochhaus, Andreas ;

Powell, Bayard L. ;

Gabrilove, Janice L. ;

Rousselot, Philippe ;

Reiffers, Josy ;

Cornelissen, Jan J. ;

Hughes, Timothy ;

Agis, Hermine ;

Fischer, Thomas ;

Verhoef, Gregor ;

Shepherd, John ;

Saglio, Giuseppe ;

Gratwohl, Alois ;

Nielsen, Johan L. ;

Radich, Jerald P. ;

Simonsson, Bengt ;

Taylor, Kerry ;

Baccarani, Michele ;

So, Charlene ;

Letvak, Laurie ;

Larson, Richard A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417

[6] Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms [J].

Feenstra, Jelena D. Milosevic ;

Nivarthi, Harini ;

Gisslinger, Heinz ;

Leroy, Emilie ;

Rumi, Elisa ;

Chachoua, Ilyas ;

Bagienski, Klaudia ;

Kubesova, Blanka ;

Pietra, Daniela ;

Gisslinger, Bettina ;

Milanesi, Chiara ;

Jaeger, Roland ;

Chen, Doris ;

Berg, Tiina ;

Schalling, Martin ;

Schuster, Michael ;

Bock, Christoph ;

Constantinescu, Stefan N. ;

Cazzola, Mario ;

Kralovics, Robert .

BLOOD, 2016, 127 (03) :325-332

[7] Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance [J].

Gangat, Naseema ;

Tefferi, Ayalew ;

Thanarajasingam, Gita ;

Patnaik, Mrinal ;

Schwager, Susan ;

Ketterling, Rhett ;

Wolanskyj, Alexandra P. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (01) :17-21

[8] Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Hochhaus, A. ;

Saussele, S. ;

Rosti, G. ;

Mahon, F. -X. ;

Janssen, J. J. W. M. ;

Hjorth-Hansen, H. ;

Richter, J. ;

Buske, C. .

ANNALS OF ONCOLOGY, 2017, 28 :41-51

[9] Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results [J].

Hughes, Timothy ;

Deininger, Michael ;

Hochhaus, Andreas ;

Branford, Susan ;

Radich, Jerald ;

Kaecla, Jaspal ;

Baccarani, Michele ;

Cortes, Jorge ;

Cross, Nicholas C. P. ;

Druker, Brian J. ;

Gabert, Jean ;

Grimwade, David ;

Hehlmann, Ruediger ;

Kamel-Reid, Suzanne ;

Lipton, Jeffrey H. ;

Longtine, Janina ;

Martinelli, Giovanni ;

Saglio, Giuseppe ;

Soverini, Simona ;

Stock, Wendy ;

Goldman, John M. .

BLOOD, 2006, 108 (01) :28-37

[10] Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib [J].

Hughes, Timothy P. ;

Saglio, Giuseppe ;

Kantarjian, Hagop M. ;

Guilhot, Francois ;

Niederwieser, Dietger ;

Rosti, Gianantonio ;

Nakaseko, Chiaki ;

De Souza, Carmino Antonio ;

Kalaycio, Matt E. ;

Meier, Stephan ;

Fan, Xiaolin ;

Menssen, Hans D. ;

Larson, Richard A. ;

Hochhaus, Andreas .

BLOOD, 2014, 123 (09) :1353-1360

← 1 2 3 4 →